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Abstract
Introduction
Pneumococcal colonisation is regarded as a pre-requisite for developing pneumococcal dis-
ease. In children previous studies have reported pneumococcal colonisation to be a symp-
tomatic event and described a relationship between symptom severity/frequency and
colonisation density. The evidence for this in adults is lacking in the literature. This study
uses the experimental human pneumococcal challenge (EHPC) model to explore whether
pneumococcal colonisation is a symptomatic event in healthy adults.
Methods
Healthy participants aged 18–50 were recruited and inoculated intra-nasally with either
Streptococcus pneumoniae (serotypes 6B, 23F) or saline as a control. Respiratory viral
swabs were obtained prior to inoculation. Nasal and non-nasal symptoms were then
assessed using a modified Likert score between 1 (no symptoms) to 7 (cannot function).
The rate of symptoms reported between the two groups was compared and a correlation
analysis performed.
Results
Data from 54 participants were analysed. 46 were inoculated with S. pneumoniae (29 with
serotype 6B, 17 with serotype 23F) and 8 received saline (control). In total, 14 became
experimentally colonised (30.4%), all of which were inoculated with serotype 6B. There was
no statistically significant difference in nasal (p = 0.45) or non-nasal symptoms (p = 0.28)
between the inoculation group and the control group. In those who were colonised there
was no direct correlation between colonisation density and symptom severity. In the 22%
(12/52) who were co-colonised, with pneumococcus and respiratory viruses, there was no
statistical difference in either nasal or non-nasal symptoms (virus positive p = 0.74 and virus
negative p = 1.0).
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Conclusion
Pneumococcal colonisation using the EHPC model is asymptomatic in healthy adults,
regardless of pneumococcal density or viral co-colonisation.
Introduction
Streptococcus pneumoniae (pneumococcus, SPN) frequently colonises the human nasophar-
ynx, with 40–95% of infants and 10–25% of adults being colonised at any one time[1]. Pneu-
mococcal/SPN colonisation rates also vary with geographical location, genetics and
socioeconomic background[2]. SPN colonisation is a dynamic process. Although multiple
SPN serotypes can both simultaneously and sequentially colonise, one serotype is usually the
predominant current coloniser[3]. In addition interspecies competition occurs between resi-
dent flora and potential colonisers including S.pneumoniae, H.influenzae and S.aureus[4].
Colonisation of the nasopharynx is considered a pre-requisite for SPN infections including
pneumonia, sepsis, meningitis and otitis media. However, most colonisation episodes will not
lead to subsequent disease. Pneumococcal colonisation is also thought to be the predominant
source of immunological boosting against SPN infection in both children and adults[5, 6].
SPN colonisation appears to be asymptomatic in murine models[7] and in adults, however
the current data are limited[8]. Previous studies in children have demonstrated mild nasal
symptoms following SPN colonisation however when adjusted for age this relationship was
weak[9]. Other studies have reported a relationship between symptom severity, pneumococcal
density and pneumococcal/viral co-colonisation in children[10]. Pneumococcal colonisation
may cause nasal symptoms in two ways; the bacteria could induce host secretions and inflam-
matory responses or in co-colonised individuals (pneumococcus and virus) due to viral prolif-
eration inducing rhinitis[9]. Some studies have concluded that the presence of respiratory
viruses and/or other bacteria within the nasopharynx are the main cause of symptoms; this col-
onisation in turn increases the rate of pneumococcal colonisation[9].
The novel experimental pneumococcal challenge model (EHPC) model mimics natural
pneumococcal colonisation in healthy human adults and has been used to effectively study
mucosal immunity and as a platform to test the efficacy of pneumococcal vaccines in rando-
mised control trials[11, 12]. We aimed to use the EHPC model to investigate if the process of
nasopharyngeal pneumococcal colonisation leads to symptoms.
Methods
We recruited non-smoking healthy participants aged 18–60 years old (self-selection) as part of
a larger EHPC dose ranging study between 24th May 2012 to 23rd October 2012, with follow
up until January 2013. A modified CONSORT flow diagram is shown in Fig 1. Specimen col-
lection and sample processing were conducted in Liverpool, UK. All participants gave written,
informed consent. Ethical permission was granted by local NHS Research and Ethics Commit-
tee (REC) (11/NW/0592 Liverpool-East, date 11/10/2011). This study was retrospectively reg-
istered on the ISRCTN database (ISRCTN85403723) as this was not a mandatory requirement
at the time of recruitment. All ongoing and related trials for this intervention are now prospec-
tively registered with ISRCTN. Exclusion criteria included natural pneumococcal colonisation
at baseline, any chronic medical condition or regular medication (study participation could
put the participant at increased risk of pneumococcal disease) and regular contact with an at-
risk individual such as young children (study participation could put the at-risk individual at
increased risk of pneumococcal disease).
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Participants were nasally inoculated with 8x104, 1.6x105, or 3.2x105 mid-log phase colony
forming units (CFU) S. pneumoniae (prepared as previously described)[6]. Bacterial inocula-
tion density was confirmed by serial dilutions of the inoculation stock onto blood agar
(Oxoid). Two serotypes were used; 6B and 23F, both were fully sensitive to penicillin. 46 par-
ticipants were allocated to be inoculated with S. pneumoniae (SPN 6B or 23F) as part of a dose-
ranging study and 8 participants inoculated with saline as a control group. They were blinded
to their groups.
Pre-inoculation oropharyngeal swabs were assayed for respiratory viruses using multiplex
Polymerase Chain reaction (PCR) as previously published [13]. The PCR assay panel detected
Influenza A and B, Respiratory syncytial virus, Human metapneumovirus, Human rhinovirus,
Parainfluenza viruses 1–4 and Coronaviruses OC43, NL63, 229E and HKU1. Nasopharyngeal
colonisation was assessed in nasal washes (Nacleiro technique, as previously described)
Fig 1. Modified CONSORT diagram.
https://doi.org/10.1371/journal.pone.0229558.g001
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collected at day 2, 7 and 14 post inoculation[14]. Pneumococcal colonisation status and density
in nasal washes was determined by classical culture as previously described[6, 14].
Participants were prompted to complete a daily symptom log on the day of inoculation
(baseline) and daily for 7 days post-inoculation. The symptom log consisted of a 7-point visual
analogue scale (a type of Likert scale) which assessed five nasal and five non-nasal symptoms
[15]. The only modification to the validated questionnaire was the removal of ‘mental func-
tion’ as a non-nasal symptom (Fig 2). Scores�2 were considered ‘symptomatic’. The score
awarded at inoculation (day 0) was considered their baseline score, the participant was consid-
ered symptomatic if the score went above baseline and� 2.
Graphical and statistical analyses were performed using GraphPad version 5.0 (GraphPad
Software, La Jolla, CA, USA) and Microsoft Excel, with a p-value of<0.05 considered signifi-
cant. Rates of symptoms reported between groups were compared using Fisher’s exact tests
and Chi square where appropriate. Correlation analysis was performed using Spearman’s rank
text. The daily symptom logs were collected at the next scheduled visit following completion.
Results
Fifty-five participants were recruited with an age range of 19–49 years old over a 6- month
period from24/04/2012-23/10/2012. Participants with incomplete symptom severity score logs
Fig 2. Participant symptom log. A severity score<2 was considered asymptomatic.
https://doi.org/10.1371/journal.pone.0229558.g002
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were excluded, therefore data from 54 participants were analysed. 46 participants were inocu-
lated with SPN (29 with 6B, 17 with 23F) and 8 with saline (control group). Participants inocu-
lated with 6B, 23F and saline were similar in age and gender distribution. In total, 14
participants became experimentally colonised (30.4%), all of which were inoculated with sero-
type 6B. None of the participants in the control group developed natural SPN colonisation
during the study. Overall 72% (39/54) of participants reported either or both nasal or non-
nasal symptoms during the 7 days post-inoculation. Of these symptoms, similar rates of nasal
and non-nasal symptoms were reported; 59% (32/54) of participants reported nasal symptoms
and 56% (30/54) reported non-nasal symptoms.
No statistical difference was seen between number of participants who reported symptoms
in the experimental SPN positive or negative group. Similar rates of experimental SPN positive
participants reported nasal symptoms (71%, 10/14) and non-nasal symptoms (57%, 8/14) com-
pared to experimental SPN negative participants (50%, 16/32 in nasal (OR 2.50 [95% CI: 0.65–
9.66] P = 0.212) and non-nasal (OR 1.33 [95% CI: 0.38–4.73] P = 0.754). See Fig 3.
Nasal SPN inoculation did not lead to greater rates of reported symptoms when compared
to the control (saline inoculation) group, as show in Fig 4. Nasal symptoms were reported by
75% (6/8) of participants inoculated with saline compared to 57% (26/46) of those who were
inoculated with SPN, no statistical difference was seen (p = 0.45). Similarly, no statistical dif-
ference was seen with the reporting of non-nasal symptoms 24/46 (52%) post-SPN inoculation
compared to post-saline inoculation 6/8 (75%), (p = 0.28). Participants that reported ‘any
symptom’ were higher in the control group 100% (8/8) compared to 67% (31/46) in the inocu-
lation group, this was not statistically significant (p = 0.09).
Of the 14 participants colonised with SPN, colonisation density was measured at days 2 and
7. No direct correlation was seen between SPN density and the mean symptom severity score
at day 2 and day 7 for nasal (p = 0.86 Spearman’s correlation) and non-nasal symptoms
(p = 0.83 Spearman’s correlation), Fig 5.
Viral colonisation data was available for 96% (52/54) participants at baseline. Viral coloni-
sation was detected in 22% (12/52) of participants, 2 were inoculated with saline and 10 with
SPN [serotype 23F (n = 2) and 6B (n = 8)]. There was no increase in nasal or non-nasal symp-
toms respectively in virus positive 8/12 (67%) and 7/12 (58%) respectively compared to virus
negative participants 23/40 (58% for both symptoms), p = 0.74 and p = 1.0. Experimental SPN
colonisation rates were higher in the presence of virus 6/10 (60%) compared to 8/35 (23%) in
virus negative participants (p =<0.05). Virus and SPN positive (Co-colonised) participants
did not report greater rates of nasal or non-nasal symptoms [4/6, (60%) for both symptoms],
when compared to SPN positive only [nasal symptoms 6/8 (75%), OR 0.67 [95% CI: 0.06–
6.88], P = 1.000), non-nasal symptoms 4/8 (50%), OR 2.00 [95% CI: 0.22–17.90] P = 0.627]
and virus positive only [nasal symptoms 3/4 (75%) OR 3.23 [0.30–35.13] P = 0.600, non-nasal
symptoms 2/4 (50%] OR 0.93 [95% CI: 0.11–7.59] P = 1.000). This is shown in Fig 6.
Discussion
This study, with a clear methodology, provides evidence supporting the hypothesis that experi-
mental pneumococcal (SPN) colonisation in adults is an asymptomatic event. This novel use
of a human challenge model allowed the study of pneumococcal colonisation and symptomol-
ogy in a controlled environment. The carriage rate of pneumococcus in this study was 30.4%
and all with SPN6B. This is higher than the ‘natural rate’, due to the artificial introduction of
the bacteria directly into the nasopharynx. This SPN 6B (BHN418) is known from epidemio-
logical studies to have a very low prevalence in the community, therefore the participants are
unlikely to have been exposed to it previously. The carriage rate for those inoculated with 23F
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Fig 3. Comparison of nasal, non-nasal and all symptoms between experimental SPN positive and negative
participants. Each bar chart shows the percentage of carriage positive (N = 14) and carriage negative (N = 32)
participants, who reported symptoms (nasal, non-nasal and all symptoms) after inoculation with Streptococcus
pneumoniae serotypes 6B or 23F. Participants were deemed symptomatic if they scored>2, or>1 point above
baseline for any of the five nasal or non-nasal symptoms in the visual analogue scale. The number of participants
reporting symptoms between carriage positive and negative status were statistically compared using Fishers Exact and
deemed significant if P =�0.05. There was no significant difference in the number of participants reporting nasal (OR
2.50 [95% CI: 0.65–9.66] P = 0.212), non-nasal (OR 1.33 [95% CI: 0.38–4.73] P = 0.754) or all symptoms (OR 1.31
[95% CI: 0.33 to 5.16] P = 1.000) between carriage positive and carriage negative participants.
https://doi.org/10.1371/journal.pone.0229558.g003
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Fig 4. Comparison of nasal, non-nasal and all symptoms between participants inoculated with S. pneumoniae
compared to those inoculated with normal saline (control). Each bar chart shows the percentage of participants
inoculated with S. pneumoniae (SPN) serotypes 6B and 23F (N = 46) and normal saline (control) (N = 8) reporting
symptoms (nasal, non- nasal and all symptoms) after inoculation. Participants were deemed symptomatic if they
scored>2, or>1 point above baseline for any of the five nasal or non-nasal symptoms on the visual analogue scale.
The number of participants reporting symptoms between inoculation with SPN and control were statistically
compared using Fishers Exact and deemed significant if P =�0.05. There was no significant difference in the number
of participants reporting nasal (OR 0.43 [95% CI: 0.08–2.38] P = 0.449), non-nasal (OR 0.36 [95% CI: 0.07–2.00]
P = 0.277) and all symptoms (OR 0.12 [95% CI: 0.01–2.21] P = 0.089).
https://doi.org/10.1371/journal.pone.0229558.g004
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was 0%. The reasons for the variability in carriage rate between serotypes is unclear but
thought to be related to the evasion of mucociliary clearance, host nutrient availability and
niche competition[8].
The strengths of this study are the robust methodology used to assess symptom severity
[15], the lack of recall bias (due to prospective daily data log completion) and the use of a con-
trol group. Using this novel human challenge model, the exact day of pneumococcal inocula-
tion and the onset and termination of each SPN colonisation episode was known allowing
association between symptoms and pneumococcal presence and density over time. The main
limitations of our study was the total sample size (n = 54), the lack of randomisation for group
allocation and the use of a single serotype of SPN.
Although a previous study in adults used a small sample size (n = 14) and did not include
the methods used to support this conclusion[16], it agrees with our data that pneumococcal
colonisation in healthy adults is indeed asymptomatic. Higher symptom severity scores were
not a predictor for colonisation.
SPN colonisation is more common in children; therefore, a limitation of this work is the
lack of generalisability of results to all age groups, however reasonable evidence exists that SPN
colonisation in children does cause nasal symptoms[10, 17]. Another limitation is that only
one serotype was assessed in this study, SPN 6B. This particular serotype is not thought to be
present in the community and therefore it is very unlikely that the participants would have
pre-existing immunity from previous exposure. A previous study suggested that the presence
of symptoms could be dependent on the serotype of pneumococcus[17]. The authors reported
that colonisation with serotype 19F was strongly associated with symptoms such as coryza,
sneezing, cough and expectoration. However, these children were recruited from a paediatric
hospital emergency room, the study did not report on the diagnosis given to these patients
therefore upper or lower respiratory infection may have been the cause of these symptoms
rather than solely SPN colonisation[17].
Rodrigues et al found that rhinitis symptoms, rates of colonisation with SPN and Haemo-
philus Influenzae (Hi) in pre-school children decreased with age. Symptoms of rhinitis were
reported using the Symptoms of Nasal Outflow Tally (SNOT) score. Both SPN and Hi
Fig 5. Correlation between pneumococcal colonisation density (SPN positive participants) and mean nasal symptom severity scores at days 2 and 7.
Spearman’s correlation was used to statistically analyse the correlation between bacterial colonisation density and the participants symptoms score on the visual
analogue scale. Participants were deemed symptomatic if they scored>2, or>1 point above baseline for any of the five nasal or non-nasal symptoms in the
visual analogue scale. No direct correlation was seen between SPN density and the mean symptom severity score at day 2 and day 7 for nasal (p = 0.86) or non-
nasal symptoms (p = 0.83).
https://doi.org/10.1371/journal.pone.0229558.g005
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Fig 6. Comparison of nasal, non-nasal and all symptoms in carriage positive and negative participants with and
without viral infection. Each bar chart shows a comparison of the percentage of carriage positive and negative
participants, after inoculation with S. pneumoniae serotype 6B or 23F, who reported symptoms (nasal, non-nasal and
all symptoms), between those infected with a virus and those without viral infection. Participants were deemed
symptomatic if they scored>2, or>1 point above baseline for any of the five nasal or non-nasal symptoms on the
visual analogue scale. The number of participants reporting symptoms between those infected with a virus and those
without viral infection were statistically compared using Fishers Exact and deemed significant if P =�0.05. There was
no significant difference in the number of participants reporting nasal, non-nasal and all symptoms between those
with viral infection and those without viral infection in both the carriage positive (nasal symptoms OR 0.67 [95% CI:
0.06–6.88], P = 1.000, non-nasal symptoms OR 2.00 [95% CI: 0.22–17.90] P = 0.627, all symptoms OR 0.67 [95% CI:
0.06–6.88] P = 1.000) and carriage negative groups (nasal symptoms OR 3.23 [0.30–35.13] P = 0.600, non-nasal
symptoms OR 0.93 [95% CI: 0.11–7.59] P = 1.000, all symptoms OR 1.50 [95% CI: 0.14–16.55] P = 1.000).
https://doi.org/10.1371/journal.pone.0229558.g006
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colonisation were strongly associated with increased SNOT scores in children <5 years
(p = 0.002 and 0.001) whereas colonisation with S. aureus was negatively associated with
SNOT scores (p = 0.04). Interestingly, 40% of asymptomatic children (low SNOT score) were
in fact SPN colonised. However, when the data was analysed considering age, the association
between SPN colonisation and SNOT scores was weak (p = 0.06) whereas the association
between SNOT scores and Hi colonisation remained strong (p = 0.003). This suggest that Hi
may stimulate rhinitis in children to increase transmission[9]. The study by Rodrigues et al
does not, however, report the effect of co-colonisation (SPN and virus) on symptoms.
Our results suggest that in adults co-colonisation (SPN and virus) is also an asymptomatic
process with similar rates of nasal and non-nasal symptoms reported in all groups. Our results
did show that asymptomatic viral infection at baseline was associated with the acquisition of
SPN colonisation in adults. This is in keeping with results in children which found that asymp-
tomatic viral infections had a large effect on SPN colonisation[18]. They reported that the pro-
portion of children with SPN colonisation was higher during prompted visits for review of
upper respiratory tract infections (URTI) symptoms rather than for regular planned study fol-
low up visits. Due to the small sample size of SPN and virus co-colonisers (n = 6), it is difficult
to make strong assumptions about the symptomology of co-infection from our study. Viral
swabs were also only performed at baseline (up to 7 days prior to inoculation) therefore we
cannot assess correlation between symptoms and viral status at each point, nor was density
measured.
In conclusion we have provided evidence to support the hypothesis that neither nasopha-
ryngeal inoculation nor experimental pneumococcal colonisation cause nasal or non-nasal
symptoms in adults. Our results suggest that asymptomatic viral infection prior to nasopha-
ryngeal inoculation or experimental SPN colonisation does not increase nasal or non-nasal
symptoms. A better understanding of the process of viral co-infection in adults and the symp-
toms caused by viral infection prior to or following acquisition of SPN colonisation is needed
and would add to this study’s preliminary data. A key question, given the difference between
adults and children, is the association between colonisation symptoms and transmission; our
study indicates that pneumococcal colonisation in adults is asymptomatic, but does not
address transmission dynamics.
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